Podcast

Speaking of Urology: What patients undergoing HIFU should expect postoperatively

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

Catch up on "Speaking of Urology":

A HIFU expert discusses his treatment criteria

Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
1 expert in this video
Selecting Between Receptor Pathway Inhibitors for mHSPC
Related Content
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
June 25th 2025

Botulinum toxin reduces PSMA therapy-related salivary gland toxicity

Benjamin P. Saylor
The approach was associated with a 30% decrease in PSMA uptake by the salivary glands without compromising the treatment’s efficacy.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
CHMP recommends EU approval of darolutamide plus ADT in mHSPC
June 20th 2025

CHMP recommends EU approval of darolutamide plus ADT in mHSPC

Hannah Clarke
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
June 18th 2025

Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC

Hannah Clarke
The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.